Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.73
-2.3%
$1.74
$1.41
$5.01
$9.57M1.1926,898 shs62,917 shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$37.01
+1.1%
$32.73
$29.31
$61.38
$4.42B0.591.53 million shs960,448 shs
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
$0.30
$0.58
$0.18
$16.00
$10.94M0.84822,537 shs309,164 shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$1.36
$1.22
$0.66
$1.55
$309.13M1.861.45 million shs696,002 shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$2.13
+3.9%
$1.75
$0.60
$3.08
$173.94M1.4394,539 shs224,260 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-5.85%+1.14%-4.84%+14.19%-55.19%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-0.11%+7.94%+5.94%-5.33%-33.39%
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
0.00%0.00%0.00%0.00%0.00%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
0.00%+11.02%+8.80%+64.85%+16.24%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-11.26%-8.07%-22.35%+207.81%+35.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.5658 of 5 stars
3.54.00.00.00.00.81.3
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
4.1995 of 5 stars
4.52.00.04.61.50.80.0
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.688 of 5 stars
3.51.00.04.71.51.70.0
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.0162 of 5 stars
3.73.00.00.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50791.83% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.93
Moderate Buy$70.9292.66% Upside
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
0.00
N/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.00
Buy$7.33429.48% Upside
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.33
Buy$6.00179.72% Upside

Current Analyst Ratings Breakdown

Latest CYTK, FREQ, IMAB, GOSS, and APRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
7/9/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
6/27/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
6/26/2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
6/9/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.00
5/29/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.00
5/14/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/13/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.50M6.41N/AN/A$3.55 per share0.49
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$18.47M238.03N/AN/A($1.15) per share-32.01
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
$14.07M0.78N/AN/A$1.96 per share0.15
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$114.70M2.74N/AN/A$0.13 per share10.65
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$3.89M45.03N/AN/A$2.47 per share0.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)

Latest CYTK, FREQ, IMAB, GOSS, and APRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million
5/14/2025Q1 2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
5.90
5.90
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
5.99
5.99
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
N/A
5.81
5.81
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70
5.71
5.71
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.35
22.35

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
13.18%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
13.63%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.70%
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
16.80%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.53 million4.78 millionNo Data
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million116.20 millionOptionable
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
4636.52 million30.39 millionNot Optionable
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
180227.30 million212.07 millionOptionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable

Recent News About These Companies

I-Mab (NASDAQ:IMAB) Given Buy Rating at HC Wainwright
I-Mab (NASDAQ:IMAB) Price Target Raised to $5.00
I-Mab regains compliance with Nasdaq’s listing rule

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$1.73 -0.04 (-2.26%)
Closing price 03:58 PM Eastern
Extended Trading
$1.76 +0.03 (+1.73%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$37.01 +0.42 (+1.15%)
Closing price 04:00 PM Eastern
Extended Trading
$35.93 -1.08 (-2.92%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Frequency Therapeutics stock logo

Frequency Therapeutics NASDAQ:FREQ

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Gossamer Bio stock logo

Gossamer Bio NASDAQ:GOSS

$1.36 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.37 +0.01 (+0.74%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

I-Mab stock logo

I-Mab NASDAQ:IMAB

$2.13 +0.08 (+3.90%)
Closing price 04:00 PM Eastern
Extended Trading
$2.10 -0.03 (-1.36%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.